A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers

NCT04104997 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Syndromes

Interventions

DRUG: 5% GLH8NDE
DRUG: Placebos

Sponsor

GL Pharm Tech Corporation